TRex Bio Inc, an early-stage biotech focused on autoimmune and inflammatory
diseases, raised $116.7 mln in a U.S. IPO, pricing at the low end of its
proposed range.
2026-10-09
TRex Bio Inc, an early-stage biotech focused on autoimmune and inflammatory
diseases, raised $116.7 mln in a U.S. IPO, pricing at the low end of its
proposed range.